Proactive Investors - Run By Investors For Investors

Recce to reveal submission details from FDA

The halt will remain in place until Thursday 16th November 2017.
Recce to reveal submission details from FDA
The company's shares are in pre-open

Recce Ltd (ASX:RCE) has been granted a trading halt by the ASX pending the receipt of information from the United States Food and Drug Administration (FDA) following Recce’s recent data submission.

Recce is focused on the development of a new class of synthetic antibiotics.

The halt will remain in place until the opening of trade on Thursday 16th November 2017, or earlier if an announcement is made to the market.

View full RCE profile View Profile

Recce Ltd Timeline

Related Articles

Antigens
November 29 2018
The deal with New England Biolabs, signed in October, is expected to secure six-figure royalty sums as soon as next year
porcupine
November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use